Visceral obesity, metabolic syndrome, insulin resistance and cancer

Proceedings of the Nutrition Society

Volumn 71, Issue 1, 2012, Pages 181-189

  Doyle, Suzanne L ^a   Donohoe, Claire L ^a   Lysaght, Joanne ^a   Reynolds, John V ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Inflammation; Insulin resistance; Metabolic syndrome; Tumorigenesis; Visceral adiposity

Indexed keywords

ADIPONECTIN; I KAPPA B KINASE; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL OBESITY; BREAST CANCER; CANCER CELL; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CHRONIC INFLAMMATION; COLORECTAL CANCER; CONFERENCE PAPER; CYTOKINE PRODUCTION; ESOPHAGEAL ADENOCARCINOMA; HUMAN; HYPERINSULINEMIA; INFLAMMATORY CELL; INSULIN RESISTANCE; INTRAABDOMINAL FAT; MACROPHAGE; METABOLIC SYNDROME X; NEOPLASM; NONHUMAN; OBESITY; PROTEIN SECRETION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR GROWTH;

ADIPOKINES; DISEASE PROGRESSION; HUMANS; HYPERINSULINISM; INFLAMMATION; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; INTRA-ABDOMINAL FAT; MACROPHAGES; METABOLIC SYNDROME X; NEOPLASMS; OBESITY, ABDOMINAL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84856263295     PISSN: 00296651     EISSN: 14752719     Source Type: Journal    
DOI: 10.1017/S002966511100320X     Document Type: Conference Paper

References (126)

1. World Health Organisation (2000) Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation. World Health Organisation Technical Report Series 894, pp. 1-253. Geneva: WHO.
2. Ogden CL, Carroll MD, Curtin LR et al. (2006) Prevalence of overweight and obesity in the united states, 1999-2004. JAMA 295, 1549-1555.
3. National Health Service Information Centre (2009) Health survey for England-2008: Physical activity and fitness. http://www.ic.nhs.uk/statistics- and-data-collections/healthand-lifestyles-related-surveys/health-survey-for- england/health-survey-for-england-2008-physical-activity-and-fitness (accessed August 2011).
4. McCarthy SN, Gibney MJ & Flynn A (2002) Overweight, obesity and physical activity levels in Irish adults: Evidence from the North/South Ireland food consumption survey. Proc Nutr Soc 61, 3-7. (Pubitemid 34171039)
5. Jackson-Leach R & Lobstein T (2006) Estimated burden of paediatric obesity and co-morbidities in Europe. Part 1. The increase in the prevalence of child obesity in Europe is itself increasing. Int J Pediatr Obes 1, 26-32.
6. Serdula MK, Ivery D, Coates RJ et al. (1993) Do obese children become obese adults? A review of the literature. Prey Med 22, 167-177. (Pubitemid 23150661)
7. Klein S, Warden T & Superman HJ (2002) AGA technical review on obesity. Gastroenterology 123, 882-932. (Pubitemid 34977094)
8. René an AG, Tyson M, Egger M et al. (2008) Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 371, 569-578. (Pubitemid 351232031)
9. World Cancer Research Fund, American Institute for Cancer Research (2007) Food, Nutrition, Physical Activity and the Prevention of Cancer: Global Perspective. Washington, DC: American Institute for Cancer Research.
10. Calle EE, Rodriguez C, Walker-Thurmond K et al. (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults. N Engl J Med 348, 1625-1638. (Pubitemid 36459468)
11. Dirx MJM, Zeegers MPA, Dagnelie PC et al. (2003) Energy restriction and the risk of spontaneous mammary tumors in mice: A meta-analysis. Int J Cancer 106, 766-770. (Pubitemid 36993402)
12. Mai V, Colbert LH, Berrigan D et al. (2003) Calorie restriction and diet composition modulate spontaneous intestinal tumorigenesis in Apc(Min) mice through different mechanisms. Cancer Res 63, 1752-1755. (Pubitemid 36460832)
13. Sjostrom L, Gummesson A, Sjostrom CD et al. (2009) Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish obese subjects study): A prospective, controlled intervention trial. Lancet Oncol 10, 653-662.
14. Vague J (1956) The degree of masculine differentiation of obesities: A factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Obes Res 4, 204-212.
15. Vague J (1947) La differenciation sexuelle, facteur determinant des formes de l'obesité. Presse Medl 53, 339-340.
16. Fox CS, Massaro JM, Hoffmann U et al. (2007) Abdominal visceral and subcutaneous adipose tissue compartments. Circulation 116, 39-48.
17. Galic S, Oakhill JS & Steinberg GR (2010) Adipose tissue as an endocrine organ. Mol Cell Endocrinol 316, 129-139.
18. Alberti KGMM, Zimmet P & Shaw J (2006) Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 23, 469-480.
19. Fujioka S, Matsuzawa Y, Tokunaga K et al. (1987) Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36, 54-59. (Pubitemid 17016386)
20. Nedungadi TP & Clegg DJ (2009) Sexual dimorphism in body fat distribution and risk for cardiovascular diseases. J Cardiovasc Transl Res 2, 321-327.
21. Schapira DV, Clark RA, Wolff PA et al. (1994) Visceral obesity and breast cancer risk. Cancer 74, 632-639. (Pubitemid 24217627)
22. Beddy P, Howard J, McMahon C et al. (2010) Association of visceral adiposity with oesophageal and junctional adenocarcinomas. Br J Surg 97, 1028-1034.
23. Schoen RE, Tangen CM, Kuller LH et al. (1999) Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 91, 1147-1154. (Pubitemid 29330553)
24. Yamaji T, Iwasaki M, Sasazuki S et al. (2009) Visceral fat volume and the prevalence of colorectal adenoma. Am J Epidemiol 170, 1502-1511.
25. Nam SY, Kim BC, Han KS et al. (2010) Abdominal visceral adipose tissue predicts risk of colorectal adenoma in both sexes. Clin Gastroenterol Hepatol 8, 443-450.
26. Cowey S & Hardy RW (2006) The metabolic syndrome: A high-risk state for cancer? Am J Pathol 169, 1505-1522. (Pubitemid 351181984)
27. Giovannucci E (2007) Metabolic syndrome, hyperinsulinemia, and colon cancer: A review. Am J Clin Nutr 86, 836S-842S.
28. Colangelo LA, Gapstur SM, Gann PH et al. (2002) Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev 11, 385-391. (Pubitemid 34408218)
29. Bowers K, Albanes D, Limburg P et al. (2006) A prospective study of anthropometric and clinical measurements associated with insulin resistance syndrome and colorectal cancer in male smokers. Am J Epidemiol 164, 652-664. (Pubitemid 44453494)
30. Stocks T, Borena W, Strohmaier S et al. (2010) Cohort profile: The metabolic syndrome and cancer project (Me-Can). Int J Epidemiol 39, 660-667.
31. Stocks T, Lukanova A, Bjørge T et al. (2010) Metabolic factors and the risk of colorectal cancer in 580,000 men and women in the metabolic syndrome and cancer project (Me-Can). Cancer 117, 2398-2407.
32. Bjørge T, Stocks T, Lukanova A et al. (2010) Metabolic syndrome and endometrial carcinoma. Am J Epidemiol 171, 892-902.
33. Häggström C, Stocks T, Rapp K et al. (2011) Metabolic syndrome and risk of bladder cancer: Prospective cohort study in the metabolic syndrome and cancer project (Me-Can). Int J Cancer 128, 1890-1898.
34. Johansen D, Stocks T, Jonsson HK et al. (2010) Metabolic factors and the risk of pancreatic cancer: A prospective analysis of almost 580,000 men and women in the metabolic syndrome and cancer project. Cancer Epidemiol Biomarkers Prev 19, 2307-2317.
35. Russo A, Autelitano M & Bisanti L (2008) Metabolic syndrome and cancer risk. Eur J Cancer 44, 293-297.
36. Kang HW, Kim D, Kim HJ et al. (2009) Visceral obesity and insulin resistance as risk factors for colorectal adenoma: A cross-sectional, case-control study. Am J Gastroenterol 105, 178-187.
37. Siegel EM, Ulrich CM, Poole EM et al. (2010) The effects of obesity and obesity-related conditions on colorectal cancer prognosis. Cancer Control 17, 52-57.
38. Healy L, Howard J, Ryan A et al. (2011) Metabolic syndrome and leptin are associated with adverse pathological features in male colorectal cancer patients. Colorectal Dis 22, 281-288.
39. Healy LA, Ryan AM, Carroll P et al. (2010) Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. Clin Oncol (R Coll Radiol) 22, 281-288.
40. Shen Z, Wang S, Ye Y et al. (2010) Clinical study on the correlation between metabolic syndrome and colorectal carcinoma. ANZ J Surg 80, 331-336.
41. Moon H-G, Ju Y-T, Jeong C-Y et al. (2008) Visceral obesity may affect oncologic outcome in patients with colorectal cancer. Ann Surg Oncol 15, 1918-1922.
42. Jankowski JA, Wright NA, Meltzer SJ et al. (1999) Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 154, 965-973. (Pubitemid 29169728)
43. National Cancer Registry of Ireland (2009) http://www.ncri.ie/data (accessed August 2011).
44. Bollschweiler E, Wolfgarten E, Gutschow C et al. (2001) Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 92, 549-555. (Pubitemid 32735190)
45. Calle EE & Kaaks R (2004) Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4, 579-591. (Pubitemid 39025053)
46. Friedenberg FK, Xanthopoulos M, Foster GD et al. (2008) The association between gastroesophageal reflux disease and obesity. Am J Gastroenterol 103, 2111-2122.
47. Lagergren J, Bergstrom R & Nyren O (1999) Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 130, 883-890. (Pubitemid 29239582)
48. Ryan AM, Rowley SP, Fitzgerald AP et al. (2006) Adenocarcinoma of the oesophagus and gastric cardia: Male preponderance in association with obesity. Eur J Cancer 42, 1151-1158.
49. Ryan AM, Healy LA, Power DG et al. (2008) Barrett esophagus: Prevalence of central adiposity, metabolic syndrome, and a proinflammatory state. Ann Surg 247, 909-915. (Pubitemid 351770409)
50. Howard JM, Beddy P, Ennis D et al. (2010) Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma. Br J Surg 97, 1020-1027.
51. Elliott BE, Tam SP, Dexter D et al. (1992) Capacity of adipose tissue to promote growth and metastasis of a murine mammary carcinoma: Effect of estrogen and progesterone. Int J Cancer 51, 416-424.
52. Celis JE, Moreira JM, Cabezon T et al. (2005) Identification of extracellular and intracellular signalling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: Toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. Mol Cell Proteomics 4, 492-522. (Pubitemid 40590568)
53. Cook KS, Min HY, Johnson D et al. (1987) Adipsin: A circulating serine protease homolog secreted by adipose tissue and sciatic nerve. Science 237, 402-405.
54. Flier JS, Cook KS, Usher P et al. (1987) Severely impaired adipsin expression in genetic and acquired obesity. Science 237, 405-408.
55. Zhang Y, Proenca R, Maffei M et al. (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425-432. (Pubitemid 24365442)
56. Scherer PE, Williams S, Fogliano M et al. (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270, 26746-26749.
57. Ouchi N, Parker JL, Lugus JJ et al. (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11, 85-97.
58. Harvey AE, Lashinger LM & Hursting SD (2011) The growing challenge of obesity and cancer: An inflammatory issue. Ann NY Acad Sci 1229, 45-52.
59. Kadowaki T & Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 26, 439-451. (Pubitemid 40686653)
60. Rose DP, Komninou D & Stephenson GD (2004) Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev 5, 153-165. (Pubitemid 38998240)
61. Cummings DE & Foster KE (2003) Ghrelin-leptin tango in body-weight regulation. Gastroenterology 124, 1532-1535. (Pubitemid 36531824)
62. Pär S, Annekatrin L, Carine B et al. (2004) Obesity and colon cancer: Does leptin provide a link? Int J Cancer 109, 149-152.
63. Somasundar P, McFadden DW, Hileman SM et al. (2004) Leptin is a growth factor in cancer. J Surg Res 116, 337-349. (Pubitemid 38175325)
64. Howard JM, Pidgeon GP & Reynolds JV (2010) Leptin and gastro-intestinal malignancies. Obes Rev 11, 863-874.
65. Garofalo C & Surmacz E (2006) Leptin and cancer. J Cell Physiol 207, 12-22.
66. Bergman RN & Ader M (2000) Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 11, 351-356.
67. Ebeling P & Koivisto V (1994) Non-esterified fatty acids regulate lipid and glucose oxidation and glycogen synthesis in healthy man. Diabetologia 37, 202-209. (Pubitemid 24042891)
68. Moller DE & Flier JS (1991) Insulin resistance-mechanisms, syndromes, and implications. N Engl J Med 325, 938-948.
69. Wajchenberg BL (2000) Subcutaneous and visceral adipose tissue: Their relation to the metabolic syndrome. Endocr Rev 21, 697-738. (Pubitemid 32113289)
70. Fasshauer M & Paschke R (2003) Regulation of adipocytokines and insulin resistance. Diabetologia 46, 1594-1603. (Pubitemid 38005321)
71. Greenberg AS & McDaniel ML (2002) Identifying the links between obesity, insulin resistance and beta-cell function: Potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 32, Suppl. 3, 24-34. (Pubitemid 41704997)
72. Stocks T, Rapp K, Bjørge T et al. (2009) Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (Me-Can): Analysis of six prospective cohorts. PLoS Med 6, e1000201.
73. Hsing AW, Gao Y-T, Chua S et al. (2003) Insulin resistance and prostate cancer risk. J Natl Cancer Inst 95, 67-71. (Pubitemid 36124297)
74. Yang Y-X, Hennessy S & Lewis JD (2004) Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 127, 1044-1050. (Pubitemid 39345873)
75. Osborne CK, Bolan G, Monaco ME et al. (1976) Hormone responsive human breast cancer in long-term tissue culture: Effect of insulin. Proc Natl Acad Sci USA 73, 4536-4540. (Pubitemid 8013935)
76. Pollak M (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8, 915-928.
77. Frasca F, Pandini G, Sciacca L et al. (2008) The role of insulin receptors and IGF-1 receptors in cancer and other diseases. Arch Physiol Biochem 114, 23-37. (Pubitemid 351998752)
78. Samani AA, Yakar S, LeRoith D et al. (2007) The role of the IGF system in cancer growth and metastasis: Overview and recent insights. Endocr Rev 28, 20-47. (Pubitemid 46220849)
79. Jones JI & Clemmons DR (1995) Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 16, 3-34.
80. Coussens LM & Werb Z (2002) Inflammation and cancer. Nature 420, 860-867. (Pubitemid 36019639)
81. Chan JM, Stampfer MJ, Giovannucci E et al. (1998) Plasma insulin-like growth factor-1 and prostate cancer risk: A prospective study. Science 279, 563-566. (Pubitemid 28067285)
82. Ma J, Pollak MN, Giovannucci E et al. (1999) Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-1 and IGF-binding protein-3. J. Natl. Cancer Inst. 91, 620-625. (Pubitemid 29194048)
83. Renehan AG, Frystyk J & Flyvbjerg A (2006) Obesity and cancer risk: The role of the insulin-IGF axis. Trends Endocrinol Metab 17, 328-336. (Pubitemid 44397568)
84. Frystyk J, Vestbo E, Skjaerbaek C et al. (1995) Free insulinlike growth factors in human obesity. Metabolism 44, 37-44.
85. Nam SY, Lee EJ, Kim KR et al. (1997) Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes (Lond) 21, 355.
86. Wu Y, Brodt P, Sun H et al. (2010) Insulin-like growth factor-1 regulates the liver microenvironment in obese mice and promotes liver metastasis. Cancer Res 70, 57-67.
87. Lashinger LM, Malone LM, McArthur MJ et al. (2011) Genetic reduction of insulin-like growth factor-1 mimics the anticancer effects of calorie restriction on cyclooxygenase-2-driven pancreatic neoplasia. Cancer Prev Res (Phila) 4, 1030-1040.
88. Olivo-Marston SE, Hursting SD, Lavigne J et al. (2009) Genetic reduction of circulating insulin-like growth factor-1 inhibits azoxymethane-induced colon tumorigenesis in mice. Mol Carcinog 48, 1071-1076.
89. Shaw RJ & Cantley LC (2006) Ras, PI(3)K and MTOR signalling controls tumour cell growth. Nature 441, 424-430. (Pubitemid 44050136)
90. Weinstein IB (2002) Addiction to oncogenes-the achilles heal of cancer. Science 297, 63-64. (Pubitemid 34743088)
91. Weinstein IB & Joe AK (2006) Mechanisms of disease: Oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Prac Oncol 3, 448-457. (Pubitemid 44203817)
92. Perou CM, Sorlie T, Eisen MB et al. (2000) Molecular portraits of human breast tumours. Nature 406, 747-752.
93. Sørlie T, Tibshirani R, Parker J et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100, 8418-8423. (Pubitemid 36842560)
94. Sawyers C (2004) Targeted cancer therapy. Nature 432, 294-297. (Pubitemid 39551656)
95. Paik S, Shak S, Tang G et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New Engl J Med 351, 2817-2826. (Pubitemid 40051905)
96. Lynch TJ, Bell DW, Sordella R et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350, 2129-2139. (Pubitemid 38637993)
97. Taron M, Ichinose Y, Rosell R et al. (2005) Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 11, 5878-5885. (Pubitemid 41170316)
98. Huang P, Han J & Hui L (2010) MAPK signalling in inflammation- associated cancer development. Protein Cell 1, 218-226.
99. Yu H, Pardoll D & Jove R (2009) STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 9, 798-809.
100. Aggarwal BB, Kunnumakkara AB, Harikumar KB et al. (2009) Signal transducer and activator of transcription-3, inflammation, and cancer. Ann NY Acad Sci 1171, 59-76.
101. Sebolt-Leopold JS & Herrera R (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4, 937-947. (Pubitemid 39626217)
102. Liu P, Cheng H, Roberts TM et al. (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8, 627-644.
103. Jing N & Tweardy DJ (2005) Targeting STAT3 in cancer therapy. Anticancer Drugs 16, 601-607. (Pubitemid 40863092)
104. Creighton CJ, Sada YH, Zhang Y et al. (2011) A gene transcription signature of obesity in breast cancer. Breast Cancer Res Treat (Epublication ahead of print version).
105. Moore T, Beltran L, Carbajal S et al. (2008) Dietary energy balance modulates signalling through the Akt/mammalian target of rapamycin pathways in multiple epithelial tissues. Cancer Prev Res (Phila) 1, 65-76.
106. Algire C, Amrein L, Zakikhani M et al. (2010) Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer 17, 351-360.
107. Sharma SD & Katiyar SK (2010) Leptin deficiencyinduced obesity exacerbates ultraviolet b radiation-induced cyclooxygenase-2 expression and cell survival signals in ultraviolet b-irradiated mouse skin. Toxicol Appl Pharmacol 244, 328-335.
108. Katiyar SK & Meeran SM (2007) Obesity increases the risk of UV radiation-induced oxidative stress and activation of MAPK and NF-kappaB signalling. Free Radic Biol Med 42, 299-310. (Pubitemid 44970534)
109. van Kruijsdijk RCM, van der Wall E & Visseren FLJ (2009) Obesity and cancer: The role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 18, 2569-2578.
110. Park EJ, Lee JH, Yu G-Y et al. (2010) Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140, 197-208.
111. Kalaany NY & Sabatini DM (2009) Tumours with PI3K activation are resistant to dietary restriction. Nature 458, 725-731.
112. Colotta F, Allavena P, Sica A et al. (2009) Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis 30, 1073-1081.
113. Sen R & Baltimore D (1986) Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 46, 705-716. (Pubitemid 16020062)
114. Chaturvedi MM, Sung B, Yadav VR et al. (2011) NF-kB addiction and its role in cancer: 'one size does not fit all'. Oncogene 30, 1615-1630.
115. Ben-Neriah Y & Karin M (2011) Inflammation meets cancer, with NF-kB as the matchmaker. Nat Immunol 12, 715-723.
116. Cai D, Yuan M, Frantz DF et al. (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-b and NF-kB. Nat Med 11, 183-190. (Pubitemid 40321354)
117. Walker FC (1963) The protective function of the greater omentum. Ann R Coll Surg Engl 33, 282-306.
118. Caspar-Bauguil S, Cousin B, Galinier A et al. (2005) Adipose tissues as an ancestral immune organ: Site-specific change in obesity. FEBS Lett. 579, 3487-3492. (Pubitemid 40897681)
119. Casten DF & Alday ES (1971) Omental transfer for revascularization of the extremities. Surg Gynecol Obstet 132, 301-304.
120. Platell C, Cooper D, Papadimitriou JM et al. (2000) The omentum. World J Gastroenterol 6, 169-176. (Pubitemid 30223590)
121. Lynch L, O'Shea D, Winter DC et al. (2009) Invariant NKT cells and CD1d + cells amass in human omentum and are depleted in patients with cancer and obesity. Eur J Immunol 39, 1893-1901.
122. Rangel-Moreno J, Moyron-Quiroz JE, Carragher DM et al. (2009) Omental milky spots develop in the absence of lymphoid tissue-inducer cells and support B and T cell responses to peritoneal antigens. Immunity 30, 731-743.
123. Morris DL, Singer K & Lumeng CN (2011) Adipose tissue macrophages: Phenotypic plasticity and diversity in lean and obese states. Curr Opin Clin Nutr Metab Care 14, 341-346.
124. Lumeng CN, Bodzin JL & Saltiel AR (2007) Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 117, 175-184. (Pubitemid 46048464)
125. Nishimura S, Manabe I, Nagasaki M et al. (2009) CD8 + effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 15, 914-920.
126. Lysaght J, Allott EH, Donohoe CL et al. (2011) T lymphocyte activation in visceral adipose tissue of patients with oesophageal adenocarcinoma. Br J Surg 98, 964-974.